Selective estrogen receptor modulators (SERMs): A review of clinical data

This publication has 51 references indexed in Scilit:

• Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial
  The Lancet, 2013
• Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: Preventing Breast Cancer
  Cancer Prevention Research, 2010
• Endometrial safety
  Menopause, 2010
• Impact of Raloxifene or Tamoxifen Use on Endometrial Cancer Risk: A Population-Based Case-Control Study
  Journal of Clinical Oncology, 2008
• Tamoxifen for the Prevention of Breast Cancer: Late Results of the Italian Randomized Tamoxifen Prevention Trial Among Women With Hysterectomy
  JNCI: Journal of the National Cancer Institute, 2007
• Effects of Tamoxifen vs Raloxifene on the Risk of Developing Invasive Breast Cancer and Other Disease OutcomesThe NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 Trial
  JAMA, 2006
• Arzoxifene: the development and clinical outcome of an ideal SERM
  Expert Opinion on Investigational Drugs, 2006
• Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials
  The Lancet, 2005
• Effects of ospemifene, a novel SERM, on hormones, genital tract, climacteric symptoms, and quality of life in postmenopausal women: a double-blind, randomized trial
  Menopause, 2003
• Overview of the main outcomes in breast-cancer prevention trials
  The Lancet, 2003